Physician profile
Kumar Vasudevan
NPI 1932467594
$7,449.26
in general payments reported to CMS, 2019-2025
9 companies · $3,198 in 2025
The $3,198 reported for 2025 was more than what 75% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $123 · 2021: $1,205 · 2023: $2,879 · 2024: $43.76 · 2025: $3,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,228 · Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,227.93 |
| Food and Beverage | $893.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,031.82 | 2023-2025 | Cd Horizon Spinal System, Stealth Autoguide System, Stealthstation S8 Platform |
| Nuvasive, INC. | $1,007.78 | 2021 | |
| Gt Medical Technologies, INC | $197.17 | 2021 | |
| Novocure INC. | $73.02 | 2020 | |
| Medtronic USA, INC. | $50.00 | 2020 | |
| Baxter Healthcare | $30.24 | 2023 | Floseal |
| Augmedics INC. | $25.65 | 2025 | Xvision |
| Pacira Pharmaceuticals Incorporated | $18.82 | 2023 | Exparel, Zilretta, Iovera |
| Cerapedics INC. | $14.76 | 2025 | I-Factor Peptide Enhanced Bone Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Vasudevan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.